Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany

Johanna Koehler, Barbara Ritzer, Simon Weidlich, Friedemann Gebhardt, Chlodwig Kirchhoff, Jens Gempt, Christiane Querbach, Dieter Hoffmann, Bernhard Haller, Roland M. Schmid, Jochen Schneider, Christoph D. Spinner, Roman Iakoubov

Publikation: Beitrag in FachzeitschriftArtikelBegutachtung

8 Zitate (Scopus)

Abstract

Additional treatment options for coronavirus disease (COVID-19) are urgently needed, particularly for populations at high risk of severe disease. This cross-sectional, retrospective study characterized the outcomes of 43 patients with nosocomial severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection with and without treatment using monoclonal SARS-CoV-2 spike antibodies (bamlanivimab or casirivimab/imdevimab). Our results indicate that treatment with monoclonal antibodies results in a significant decrease in disease progression and mortality when used for asymptomatic patients with early SARS-CoV-2 infection.

OriginalspracheEnglisch
Seiten (von - bis)1313-1318
Seitenumfang6
FachzeitschriftInfection
Jahrgang49
Ausgabenummer6
DOIs
PublikationsstatusVeröffentlicht - Dez. 2021
Extern publiziertJa

Fingerprint

Untersuchen Sie die Forschungsthemen von „Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany“. Zusammen bilden sie einen einzigartigen Fingerprint.

Dieses zitieren